Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R3, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy.
Type:
Grant
Filed:
July 26, 2002
Date of Patent:
May 29, 2007
Assignee:
AstraZeneca AB
Inventors:
David Cheshire, Stephen Connolly, Antonio Mete
Abstract: The invention concerns the use of the quinazoline derivatives of Formula (I) wherein each of m, R1, Z, n and R3 have any of the meanings defined in the description in the manufacture of a medicament for use in the prevention or treatment of T cell mediated diseases or medical conditions in a warm-blooded animal
Abstract: The invention is based on the identification of a novel splice variant of human cannabinoid 1 (CB1) receptor, termed CB1b, and its use in the identification of therapeutic agents and in the diagnosis, prevention and treatment of CB associated disorders such as obesity, psychiatric, pain and neurological disorders.
Type:
Application
Filed:
January 11, 2007
Publication date:
May 24, 2007
Applicant:
ASTRAZENECA AB
Inventors:
Huy Vu, Thierry Groblewski, Peter Greasley
Abstract: A method of treating at least one symptom or condition associated with but not limited to: 1) Substance-Related Disorders including but not limited to Substance Dependence, Substance Abuse, Substance Intoxication, Substance Withdrawal, Alcohol-Related Disorders, Amphetamine (or Amphetamine-Like)-Related Disorders, Caffeine-Related Disorders, Cannabis-Related Disorders, Cocaine-Related Disorders, Hallucinogen-Related Disorders, Inhalant-Related Disorders, Nicotine-Related Disorders, Opioid-Related Disorders, Phencyclidine (or Phencyclidine-Like)-Related Disorders, and Sedative-, Hypnotic- or Anxiolytic-Related Disorders. 2) Attention-Deficit and Disruptive Behavior Disorders. 3) Eating Disorders. 4) Personality Disorders including but not limited to Obsessive-Compulsive Personality Disorder. 5) Impulse-Control Disorders, comprising administering an effective amount of Formula I or its pharmaceutically acceptable salt.
Type:
Application
Filed:
January 6, 2006
Publication date:
May 24, 2007
Applicant:
AstraZeneca AB
Inventors:
Patricia Davis, Jeffrey Goldstein, Scott Grimm, Helen Winter, Raymond Suckow
Abstract: An automatically operable safety shield system for use with a syringe that comprises an inner holder in which said syringe may be inserted and an outer shield mounted outwards from the inner holder axially movable between retracted and extended positions in which a spring positioned between said inner holder and said outer shield urging the outer shield to its extended position and the inner holder having at least one first opening, distally thereto, at least one first indentation, and the outer shield having at least one first stop member engageable with the opening when the outer shield is in the retracted position engageable with the first indentation when the outer shield is in the extended position and the outer shield may be released from its retracted position by action of a trigger positioned within the inner holder or by protrusion on the syringe plunger.
Abstract: A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Type:
Grant
Filed:
May 27, 2004
Date of Patent:
May 22, 2007
Assignee:
AstraZeneca AB
Inventors:
Alan Roy Dearn, Sarah Louise Williamson, John Simon Summers, Trevor John Coomber
Abstract: The present invention relates to a sample presentation apparatus for use in analyzing equipment for pharmaceutical products, for example solid dosage forms such as a tablet, a pellet or a capsule. The invention further relates to a method for presentation of samples to the analyzing equipment. Samples are sequentially fed through at least one predetermined analyzing position (6) wherein at least one measuring radiation beam irradiates the sample (14) when it is located in the analyzing position characterized in that there is at least one two-piece means (9, 39) for temporarily fixing each sample at said analyzing position (6), the two-piece means comprises a first and a second sample holding part arranged at the analyzing position in which the two-piece means is adapted to move between an open position wherein a sample is provided for analysis, and a closed fixing position wherein a sample is analyzed.
Type:
Grant
Filed:
January 26, 2001
Date of Patent:
May 22, 2007
Assignee:
AstraZeneca AB
Inventors:
Staffan Folestad, Kurt Lundström, Göran Östling
Abstract: The invention relates to a processing method and apparatus, more particularly, to processing a body so as to remove any electrostatic charge and improve inhaler performance in drug delivery to the respiratory tract.
Abstract: The use of compounds of formula (I) wherein variable groups are defined within; in the manufacture of medicaments for use in the inhibition of 11?HSD1, process for making them, certain compounds within the definition of the formula (I) and pharmaceutical compositions comprising them are described. The compounds are useful in the treatment of metabolic syndrome, diabetes and obesity.
Type:
Application
Filed:
November 4, 2004
Publication date:
May 17, 2007
Applicant:
AstraZeneca R&D Alderley
Inventors:
Peter Barton, Roger Butlin, Janet Pease
Abstract: There is provided substantially crystalline forms of 4-({3-[7-(3,3-dimethyl-2-oxobutyl) -9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]propyl}amino)benzo-nitrile; tert-butyl 2 -{7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate; tert-butyl 2-{7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate; or tert-butyl 2-{7-[2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of cardiac arhythmias.
Type:
Grant
Filed:
April 12, 2002
Date of Patent:
May 15, 2007
Assignee:
Astrazeneca AB
Inventors:
Neil Barnwell, Annika Björe, Lal Cheema, David Cladingboel, Adam Herring, Karin Lövqvist
Abstract: Compounds of formula I: wherein A and R1 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
Type:
Application
Filed:
November 15, 2004
Publication date:
May 10, 2007
Applicant:
AstraZeneca AB
Inventors:
James Empfield, Eifion Phillips, Scott Throner
Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
Type:
Application
Filed:
November 26, 2004
Publication date:
May 10, 2007
Applicants:
ASTRAZENECA AB, DYAX CORP.
Inventors:
Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, Rene Hoet, Henricus Hoogenboom, Simon Hufton, Christian Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
Abstract: Compounds of formula (I) wherein RF1, RF2, Z, R1, R2, Ar, X and Y are as dcfined in thc specification as wcll as salts and pharmaceutical compositions including the compounds were prepared. These compounds are useful in therapy, in particular in the management of pain.
Type:
Application
Filed:
October 15, 2003
Publication date:
May 10, 2007
Applicant:
AstraZeneca AB R&D Headquarters Global Intellectual Property Patents
Inventors:
Daniel Page, Christopher Walpole, Hua Yang
Abstract: An apparatus for use in sampling material on-line in a process system, comprising a sample collector (1) for receiving a sample of material, an elongate shaft (10) defining a passageway (14) carrying a measurement probe (11) for taking measurements from a colelcted sample, a pressurised fluid supply (31) connected to the passageway for delivering a pressurised fluid through the passageway to the sample collector for displacing the collected sample and a nozzle (33) provided at the distal end of the measurement probe (11) for distributing the pressurised fluid to the sample collector for displacing the collected sample from the sample collector (1).
Type:
Grant
Filed:
July 12, 2005
Date of Patent:
May 8, 2007
Assignee:
AstraZeneca AB
Inventors:
Lennart Björk, Staffan Folestad, Mats Johansson, Anders Klevensparr, Ingela Niklasson Björn
Abstract: Compounds of formula I: wherein A, D, Ar1, E and Ar2 are as defined in the specification, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially in the treatment or prophylaxis of psychotic and intellectual impairment disorders.
Abstract: The invention provides crystalline forms of a polypeptide corresponding to the catalytic domain of Aurora kinase. The active site ATP binding pocket is defined by its amino acid residues and their atomic coordinates. This structure may be used to select or design chemical modulators of Aurora kinase, particularly Aurora inhibitors. These modulators may be used to treat diseases of cell proliferation, e.g. cancer.
Type:
Grant
Filed:
October 8, 2002
Date of Patent:
May 8, 2007
Assignee:
AstraZeneca AB
Inventors:
Malcom Anderson, Nicholas John Keen, Andrew David Bruce Pannifer, Richard Alexander Pauptit, Sian Rowsell
Abstract: The present invention provides methods for assaying the activity of DNA primases and methods for screening for compounds that modulate the activity of DNA primases.
Abstract: The present invention relates to 2,3-substituted-4,5-diarylpyrazine compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.
Abstract: There is disclosed the use of a compound of formula (I) wherein X, Y, W and Q are as defined in the specification, and pharmaceutically acceptable salts thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of the enzyme myeloperoxidase (MPO) is beneficial. Certain novel compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, together with processes for their preparation. The compounds of formulae (I) are MPO inhibitors and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders.
Abstract: The present invention relates to 3-substituted-5,6-diarylpyrazine-2-carboxamide and -2-sulfonamide compounds and their compositions, processes for their preparation, and their use in the treatment of obesity and psychiatric and neurological disorders.